Market Newsdesk

The Company’s Proposed Pharma Grade Version of Tauri-Gum™ is Being Developed Specifically to Target: Patients Subjected to Ongoing Chemotherapy Treatment (the “Indication”)

NEW YORK, NY, Dec. 18, 2020 (GLOBE NEWSWIRE) — via NewMediaWire
— Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnologies initiatives, today announced that it has entered into a Master Services Agreement (the “Agreement”) with North Carolina based Clinical Strategies & Tactics, Inc. (“CSTI”) to resume the clinical development of its proposed “Anti-Nausea” pharmaceutical grade version of Tauri-Gum™. CSTI will largely be focusing its efforts on the following: Pharmaceutical Development Strategy (“I.”), Commercialization Strategy (“II.”), and Funding Strategy (“III.”).  The Company will be working closely with CSTI’s Founder & CEO, JoAnn C. Giannone (“Ms. Giannone”), who has over 25 years’ experience effectively leading companies through the drug and medical device development process (Prior to founding CSTI, Ms. Giannone held leadership positions with Johnson & Johnson and Pharmacia).  The Company intends to fund the entirety of this Agreement, before the end of Calendar 2020.

—

I.              Pharmaceutical Development Strategy

• Clinical and Non-Clinical safety and efficacy strategy/studied (e.g., purpose, type, estimated sample size, treatment duration, etc.)
• Product development and manufacturing strategy (e.g., physical product formulation, scale up, testing, packaging, and analytical testing to meet stage-appropriate regulatory requirements)
• Regulatory submission strategy with defined regulatory milestones (e.g., pre-IND, IND, NDA, etc. and any special designations)
• Overall development costs and funding needs by milestone
• Overall development timeline
• Elements of the development program that should be prioritized for development

II.            Commercialization Strategy

• Market Assessment
• Competitive Analysis
• Product Differentiation & Market Advantage
• Target Product Profile (“TPP”)
• Market Research
• Pricing
• Reimbursement
• Draft Forecast

III.           Funding Strategy

• Non-Dilutive Options
• Commercial Partners, Venture Funds, Universities, Philanthropic Opportunities, Patient Advocacy Groups, etc.

—

The delivery system for this proposed Pharmaceutical version is a modified version (substantially higher concentration of CBD) of the existing “Tauri-Gum™” chewing gum formulation based on continued research and development. 

On March 18, 2020 the Company announced that it had filed a Provisional U.S. Patent covering its Pharmaceutical grade version of Tauri-Gum™. This patent application, filed with the United States Patent & Trademark Office (“U.S.P.T.O.”), is titled: “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT.”
   
U.S. Provisional Patent Application No. 62/990,709

Below – CSTI Corporate Website:

Link:  http://www.csandti.com/index.html

ABOUT TAURIGA SCIENCES INC.

Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives.  The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment.  The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant) & (Vitamin C + Zinc “Immune Booster” Tauri-Gum™ Flavor: Pear Bellini).  The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com

Complementary to the Company’s retail business, are its two ongoing biotechnology initiatives.  The first one relates to the development of a Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed to help patients that are subjected to ongoing chemotherapy treatment). On March 18, 2020, the Company announced that it filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™.  The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. The second one relates to a collaboration agreement with Aegea Biotechnologies Inc. for the co-development of a rapid, multiplexed, Novel Coronavirus (COVID-19) test with superior sensitivity and selectivity.   

On October 6, 2020, the Company announced that it has been approved to operate as a U.S. Government Vendor (CAGE CODE # 8QXV4)

On October 7, 2020 the Company disclosed a Strategic Alliance with Think BIG, LLC, Social Impact Startup Founded by CJ Wallace, Son of Christopher “The Notorious B.I.G.” Wallace.

The Company is headquartered in New York City and operates a regional office in Barcelona, Spain.  In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York.

DISCLAIMER — Forward-Looking Statements

This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in  forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.

Contact:

Tauriga Sciences, Inc.

555 Madison Avenue, 5th Floor

New York, NY  10022

Chief Executive Officer

Mr. Seth M. Shaw

Email: [email protected]

cell # (917) 796 9926

Instagram: @taurigum

Twitter: @SethMShaw

Corp. Website:  www.tauriga.com

E-Commerce Website:  www.taurigum.com

LEAD PLAINTIFF DEADLINE IS FEBRUARY 2, 2021

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York on behalf of investors who purchased or acquired the securities of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) from April 24, 2019 through November 16, 2020 (the “Class Period”).

All investors who purchased shares of Boston Scientific Corporation and incurred losses are urged to contact the firm immediately at

[email protected]

or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action or

join the case

on our website,

www.whafh.com


.

If you have incurred losses in the shares of Boston Scientific Corporation, you may,no later than February 2, 2021, request that the Court appoint you lead plaintiff of the proposed class.  Please contact Wolf Haldenstein to learn more about your rights as an investor in the shares of Boston Scientific Corporation.

CLICK HERE TO JOIN CASE

The filed complaint alleges that during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:

• the LOTUS Edge Aortic Valve System’s product delivery system was dysfunctional and threatened the continued viability of the entire product line;
• as a result, the Company had materially overstated the continued commercial viability and profitability of the LOTUS Edge Aortic Valve System; and
• as a result, the Company’s public statements were materially false and misleading at all relevant times.

On November 17, 2020, pre-market, Boston Scientific announced a global recall of all unused inventory of the LOTUS Edge Aortic Valve System due to “complexities associated with the product delivery system.” Boston Scientific also announced that “given the additional time and investment required to develop and reintroduce an enhanced delivery system, the company has chosen to retire the entire LOTUS product platform immediately.”

On this news, Boston Scientific’s stock price fell $3.00 per share, or 7.89%, to close at $35.03 per share on November 17, 2020.

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected], [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

LOS ANGELES, Dec. 18, 2020 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 19, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired . (“JOYY” or the “Company”) (NASDAQ: YY) securities between April 28, 2016 and November 18, 2020 inclusive (the “Class Period”).

If you suffered a loss on your JOYY investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/joyy-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

On November 18, 2020, Muddy Waters Research published a report entitled “YY: You Can’t Make This Stuff Up. Well…Actually You Can,” alleging that the Company “is a multibillion-dollar fraud.” The report concluded “that YY’s component businesses are a fraction of the size it reports, and that the company’s reported user metrics, revenues, and cash balances are predominantly fraudulent[,]” and that “[a]pproximately 84% of YY’s reported consolidated revenue appears to be fraudulent.”

On this news, JOYY American depositary shares (“ADSs”) price fell $26.53 per ADS, or 26%, to close at $73.66 per ADS on November 18, 2020.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) JOYY dramatically overstated its revenues from live streaming sources; (2) the majority of users at any given time were bots; (3) the Company utilized these bots to effect a roundtripping scheme that manufactured the false appearance of revenues; (4) the Company overstated its cash reserves; (5) the Company’s acquisition of Bigo was largely contrived to benefit corporate insiders; and (6) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired JOYY securities during the Class Period, you may move the Court no later than January 19, 2021 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
[email protected]
www.glancylaw.com

Shareholders with $100,000 losses or more are encouraged to contact the firm

LOS ANGELES, Dec. 18, 2020 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 19, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired K12 Inc. (“K12” or the “Company”) (NYSE: LRN) common shares between April 27, 2020 and September 18, 2020, inclusive (the “Class Period”).

If you suffered a loss on your K12 investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/k12-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

On August 26, 2020, reports surfaced that K12’s training for teachers on its online education platform in Miami-Dade County Public Schools, one of the largest school districts in the country, had been ineffective and “unacceptable.”

On this news, the Company’s stock price fell $5.87, or 13.5%, over the course of two trading days to close at $37.70 on August 27, 2020.

On August 31, 2020, when classes in Miami-Dade started, K12’s platform experienced major technical issues, disruptions, and a series of cyberattacks. During a district Board meeting to discuss the problems with K12’s platform, the district’s superintendent revealed that the district had never executed its $15.3 million contract with K12.

On this news, the price of K12 shares fell by $3.96, or 10.2%, over the course of two trading days, to close at $34.89 on September 3, 2020.

A week later, facing overwhelming complaints from parents and teachers about K12’s platform and curriculum, the Miami-Dade County Public Schools Board voted to terminate its contract with K12.

On this news, the Company’s stock price fell by $3.21, or 9.5%, to close at $30.55 on September 10, 2020.

On September 17, 2020, due to the lack of confidence in K12’s ability to provide educational solutions for the district, the Beaufort County School Board also voted to terminate its contract with K12.

On this news, the Company’s stock price fell $1.09, or 3.9%, to close at $27.21 on September 18, 2020.

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) K12 lacked the technological capabilities, infrastructure, and expertise to support the increased demand for virtual and blended education necessitated by the global pandemic; (2) K12 lacked adequate cyberattack protocols and protections to prevent the disabling of its computer systems; (3) K12 was unable to provide the necessary levels of administrative support and training to teachers, students, and parents; and (4) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired K12 common shares during the Class Period, you may move the Court no later than  January 19, 2021 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
[email protected]
www.glancylaw.com

TORONTO, Dec. 18, 2020 (GLOBE NEWSWIRE) — Noront Resources Ltd. (“Noront” or “the Company”) (TSX Venture: NOT) announced today that the Noront Board of Directors has granted 923,815 restricted stock units (RSUs) convertible into common shares of the Company six months from the date of grant, being June 18, 2021. The RSUs were granted to various Directors, Officers and Management pursuant to Noront’s share awards plan and will be used to compensate, incentivize, and retain key members of the Board, Officers and Management team.

The issuance of the RSUs is subject to all applicable regulatory and exchange approvals.

About Noront Resources


Noront Resources Ltd. is focused on development of its high-grade Eagle’s Nest nickel, copper, platinum and palladium deposit and the world class chromite deposits including Blackbird, Black Thor, and Big Daddy, all of which are located in the James Bay Lowlands of Ontario in an emerging metals camp known as the Ring of Fire. www.norontresources.com

For more information:

Greg Rieveley
[email protected]
(416) 367-1444